双侧输精管缺如等三种不育患者CFTR基因突变筛查

目的探讨国人先天性双侧输精管缺如（CBAvD）、特发性少精子症（idiopathic oligospennia，IO）及特发性无精子症（idiopathic azoospennia，IA）患者CFFR基因有无突变，从而为患者行辅助生殖胚胎种植前是否需行常规的遗传学诊断提供依据。方法运用银染聚合酶链一单链构象多态性技术对25例CBAVD，40例IO，25例n患者周围静脉血白细胞DNA的CFTR基因的2、3、4、5、7A、8、9、10、11、12、13A、14a、14b、15B、19B、20、21、23共18个外显子进行检测。结果上述患者CFTR基因的18个外显子均未发现异常单链条带或位移。结论本组所检测的CFTR基因突变与国人精子发生尚无明确的相关性，国人在实施辅助生殖胚胎种植前是否需常规行CFFR基因突变检测有待进一步研究。     

高渗盐水支气管激发试验

气道高反应性是哮喘的重要病理生理学特征，药物直接激发试验测定气道高反应性已被广泛应用，多年来在哮喘的诊断中发挥了重要作用。然而药物直接激发测定气道高反应性存在种种不尽人意的地方，近年来国内外有较多文献报道了高渗盐激发试验。为探讨高渗盐激发试验的应用价值，笔者对此作一综述。     

亚溶解剂量的补体C5b-9复合物诱导肾小球系膜细胞增生及其NF-κB活化的作用

目的：研究亚溶解剂量补体C5b-9（SC5b-9）复合物刺激大鼠肾小球系膜细胞（GMCs）增生和细胞外基质（ECM）分泌的作用，并探讨NF-κB核转录因子是否介入SC5b-9的促增生效应。方法：体外纯培养大鼠GMCs，并行光镜、电镜及功能鉴定。质控SC5b-9后，将GMCs分为5组，即SC5b-9刺激组、SC5b-9＋PDTC组（吡咯啉烷二甲基硫脲）、ATS组、灭活人血清组及完全营养液组。应用RT-PCR检测40min PCNA和FN mRNA水平；同时应用免疫组化检测18 h GMCs增殖细胞核抗原（PCNA）、平滑肌肌动蛋白（α-SMA）和纤维粘连蛋白（FN）及细胞核内NF-κBp65表达情况。结果：实验40min，SC5b-9刺激组PCNA和FN mRNA表达上调，PDTC处理后表达则明显下降，其余3组PCNA均呈阴性，另3组FN则均有一定基础表达。SC5b-9刺激组，GMCs免疫组化显示：PCNA、α-SMA、FN、NF-κBp65表达增加，PDTC处理后则4者表达明显下调，其余各组，PCNA、α-SMA、NF-κRn65均呈阴性，FN亦有一定的基础表达．结论．SC5b-9可能通过激活NF-κR促讲GMCs增生和ECM分泌.     

Outcomes of using Firebird rapamycin eluting stents in routine coronary intervention practice: one-year results from the pilot study of Firebird in China registry

Recent clinical trials with rapamycin-eluting stents have shown very low restenosis rates.1-4 However, the higher penetration of drug eluting stent (DES) in China is being limited by the high costs of these imported devices, especially when considering multiple stenting.     

T4、φχ174D和 f2三种噬菌体对戊二醛消毒剂抵抗力的比较研究

目的筛选出消毒实验中评价消毒因子对病毒灭活效果的指示噬菌体.方法比较研究噬菌体T4、φχ174D和f2对戊二醛消毒剂的抵抗力.消毒剂对噬菌体的灭活效果采用悬液定量灭活试验、中和剂鉴定试验、噬菌体的检测采用双层琼脂法.结果①3000 mg/L的戊二醛对噬菌体T4作用20 min,或6000 mg/L的戊二醛对噬菌体T4作用5 min即可达到消毒水平(对噬菌体T4的灭活对数值(LIV)或噬菌体T4的对数减少值[LRV)(log10No-log10Nt)≥4.00 log10];②2500 mg/L的戊二醛对噬菌体φχ174D作用20 min,或5000 mg/L的戊二醛对噬菌体φχ174D作用5 min达到消毒水平;③4000 mg/L的戊二醛对噬菌体f2作用40 min,或8000 mg/L的戊二醛对噬菌体f2作用10 min达到消毒水平.结论上述三种噬菌体对戊二醛的抵抗力由强到弱为:噬菌体f2>噬菌体T4>噬菌体φχ174D.     

Magnetic Iron Oxide Nanoparticles Mediated Gene Therapy for Cancer An In Vitro Study

The aim of this study was to evaluate the feasibility and efficacy of using TRAIL gene to treat breast cancer mediated with a novel carrier - magnetic iron oxide nanoparticles (polyMAG-1000) coated with PEI. The magnetic iron oxide nanoparticles were used as gene carrier to transfect TRAIL gene into MCF-7 cells. The polyMAG-1000 without TRAIL gene was transfected into the tumor cells as negative control. TRAIL gene transfection with liposome as carrier served as positive control. The apoptosis of cells was detected with TUNEL method. The apoptosis ratio of tumor cells was measured with flow cytometry (FCM). It was found that the apoptosis occurred in the tumor cells after transfection of TRAIL gene mediated by both polyMAG-1000 and liposome. The apoptosis ratio in the group with polyMAG-1000 as gene carrier was (25.11±2.85) %, whereas it was (5.06±1.05) % in the control group with polyMAG-1000 (P＜0.01). The apoptosis ratio was as low as (18.31±2.44) % in the group with liposome as gene carrier (P＜0.05, as compared with the group with polyMAG-1000 as gene carrier). It is suggested that TRAIL gene may induce apoptosis in MCF-7 breast cancer cells. The magnetic iron oxide nanoparticles coated with PEI may be a potential gene carrier with high transfection efficacy for cancer gene therapy.